This is a good test to find out if your doctor/clinic/hospital follows research at all.
Do they know about this? Its only 2 months old.
http://www.ncbi.nlm.nih.gov/pubmed/22997997?dopt=Abstract
Acta Cardiol. 2012 Aug;67(4):431-8.
Abstract
OBJECTIVES:
Despite
large clinical trials, there is no consensus about the best
antithrombotic strategy for the secondary prevention of
non-cardioembolic ischaemic stroke.This retrospective study is the first
to combine the results of the most important trials and to integrate
data on study validity, effectiveness, adverse events, risk of
non-compliance, and cost.
METHODS:
We searched MEDLINE,
EMBASE, and the Cochrane Database (1996 to July 2011) and selected
long-term secondary prevention trials with treatment with aspirin,
dipyridamole, clopidogrel, aspirin plus dipyridamole, or aspirin plus
clopidogrel. Subgroup analyses were included to explain differences in
interpretations that could have led to the differences in guidelines.
RESULTS:
Two
trials showed a small but significant reduction with aspirin plus
dipyridamole compared to aspirin (ARR 1.5%, P < 0.05 and ARR 1.0%, P
< 0.05). There was no effect on vascular death. One trial showed a
small but statistical significant reduction with clopidogrel compared to
aspirin (ARR 0.5%, P < 0.05). The association of clopidogrel with
aspirin could not show any significant benefit compared to clopidogrel
monotherapy, nor compared to aspirin monotherapy, but showed higher
rates of adverse events. Significantly more patients discontinued
treatment with aspirin plus dipyridamole compared to aspirin monotherapy
(34.5% versus 13.4% and 29.0% versus 22.2%, P < 0.001) and
clopidogrel monotherapy (29.1% versus 22.6%, P < 0.001).
Transposition of statistical significant reductions in stroke recurrence
into clinical significance could not be supported.
CONCLUSIONS:
Despite
changes in international guidelines, aspirin monotherapy should retain
its position as the main antiplatelet agent for secondary prevention of
non-cardioembolic ischaemic stroke.
No comments:
Post a Comment